Bayer AG (OTC:BAYRY) shares took a steep dive late Monday afternoon as the U.S. Supreme Court grappled with whether to shield the chemical giant from tens of thousands of cancer lawsuits involving its popular weed killer, Roundup.
SCOTUS Weighs Billions In Liability
According to The Washington Post report, the justices are deliberating whether federal pesticide regulations preempt state-level claims that Monsanto—which Bayer acquired—failed to warn consumers about Roundup’s alleged cancer risks.
Although the Court appeared to lean toward restricting the lawsuits, Bayer’s stock plunged just before the closing bell, dropping from $11.20 to $10.70. The sharp market reaction underscores the enormous financial stakes of the courtroom debate.
The ruling will determine the trajectory of one of the largest mass-tort litigations in U.S. history, involving more than 100,000 lawsuits and costing Bayer approximately $11 billion in settlements to date.
The Federal Vs. State Clash
The legal battle focuses on the Environmental Protection Agency‘s longstanding position that glyphosate, Roundup’s active ingredient, is not carcinogenic to humans. Monsanto argues it cannot be penalized for omitting a label the federal government never mandated.
The specific case before the justices involves John Durnell, a man who was awarded $1.25 million by a jury after developing non-Hodgkin lymphoma following decades of Roundup use.
Public Health And Food Supply
Despite the push for uniform federal labeling, some justices questioned the broader impact of eliminating corporate accountability at the state level.
Defending the necessity of these lawsuits, Justice Ketanji Brown Jackson noted, “The threat of tort liability is one thing that spurs the manufacturer to go to the EPA and make sure that they’re giving them the information,” as per The Washington Post
While the American Farm Bureau Federation warns that restricting Roundup could pose a devastating risk to the nation’s food supply, environmental groups maintain that prioritizing corporate immunity over public health is an unacceptable trade-off.
BAYRY Stock Falls Amid SC Hearing
BAYRY plunged 4.46% to $$10.70 on Monday. Data shows it was down 1.02% on a year-to-date basis and up 33.42% over the last six months. It also gained 61.88% over the year.
Benzinga’s Edge Stock Rankings indicate that BAYRY maintains a weak price trend in the short, medium, and long terms, with a poor growth score.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JHVEPhoto via Shutterstock
Recent Comments